Shots:
- JCR & Acumen have entered into a joint collaboration, option, & license agreement to develop a novel therapy to treat Alzheimer’s disease leveraging JCR’s J-Brain Cargo tech
- As per the deal, JCR will receive an upfront payment & an option payment if Acumen exercises its exclusive option to develop, manufacture, & commercialize up to 2 candidates globally, along with ~$40M in development & $515M in sales milestones, plus tiered royalties
- Collaboration aims to develop a BBB-penetrating Alzheimer’s treatment by combining JCR’s J-Brain Cargo with Acumen’s AβO-selective antibodies, incl. sabirnetug, to target toxic AβOs & slow AD progression
Ref: Businesswire| Image: JCR Pharmaceuticals| Press Release
Related News:- Alexion Partners with JCR Pharmaceuticals to Develop Genomic Medicines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
